Showing posts with label solanezumab. Show all posts
Showing posts with label solanezumab. Show all posts

Tuesday, January 1, 2013

Alzheimer's Disease: Amyloid 'Proponents' Soldier On


Caregivers and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,


Your residents will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

MedPage Today

Year in Review
As part of the Year in Review series,MedPage Today reporters are revisiting major news stories and following up with an analysis of the impact of the original report, as well as subsequent news on the topic. Here's what's happened with drug development for Alzheimer's disease since we published the first 2012 piece on what appeared to be the demise of beta-amyloid as a drug target for symptomatic disease.
When drug giant Eli Lilly announced in August that both EXPEDITION trials of its anti-amyloid drug solanezumab had failed to show a significant benefit, many in the field thought that would be the end of the line for such agents, at least for patients showing clear signs of cognitive impairment.
The failure followed a string of other disappointing results with a variety of agents targeting the rogue protein.
Another monoclonal antibody drug, bapineuzumab, had also shown no clinical benefit in a large trial. Likewise, compounds aimed at inhibiting secretase enzymes responsible for producing beta-amyloid in vivo were disappointing.
And before that, an immunotherapy intended to mobilize the body's own immune system against beta-amyloid plaques had also failed.
Even staunch advocates of the so-called amyloid hypothesis in Alzheimer's disease -- which holds that beta-amyloid protein plaques are a key causative factor in the neurodegeneration that underlies the condition -- had changed their thinking.
People like John Morris, MD, of Washington University in St. Louis, were saying that, by the time symptoms appear, beta-amyloid has already done its damage. Instead, anti-amyloid drugs would be effective only if introduced much earlier in the disease process, before plaques have become extensive and before neurodegeneration has really taken hold.
But a funny thing happened -- Lilly didn't get the message that the drug was a dud. The company still believes that solanezumab has a future in treating symptomatic Alzheimer's disease.
And the company is not alone. Merck recently announced that it was taking a secretase inhibitor into a large trial in patients with symptomatic disease.
Solanezumab
The drug is a monoclonal antibody that binds to solitary, soluble strands of beta-amyloid protein, causing it to be eliminated by the body's waste-clearance mechanisms before they aggregate into insoluble plaques.
In announcing that the EXPEDITION studies had failed to meet their primary endpoints, Lilly indicated that they nevertheless had suggested a hint of benefit in some patients.
"A pre-specified secondary analysis of pooled data across both trials showed statistically significant slowing of cognitive decline in the overall study population of patients with mild-to-moderate Alzheimer's disease," the company said.
"In addition, pre-specified secondary subgroup analyses of pooled data across both studies showed a statistically significant slowing of cognitive decline in patients with mild Alzheimer's disease, but not in patients with moderate Alzheimer's disease."
And, in October, Lilly reported that another set of analyses conducted by the Alzheimer's Disease Cooperative Study consortium had backed up the firm's own interpretation of the data.
Encouraged by these findings, Lilly announced earlier this month that it would initiate another phase III study of solanezumab in patients with mild Alzheimer's disease. It had not set important details on the design and duration, but indicated that it would start by September of 2013.
MK-8931
This is Merck's oral inhibitor of beta secretase or BACE, one of the enzymes (the other principal one is gamma secretase) that cleaves beta-amyloid protein from a larger precursor molecule.
By blocking this enzyme, beta-amyloid production should be greatly diminished. As with solanezumab, the idea is that formation of insoluble plaques will be diminished as well.
A phase I study showed that MK-8931 reduced beta-amyloid protein levels in cerebrospinal fluid by more than 90% in healthy individuals.
With Merck's announcement that it was commencing a phase II/III trial with MK-8931, it is the most advanced of several BACE inhibitors in development.
The 78-week trial, dubbed EPOCH, will initially test three doses of the drug against placebo, to be followed with a larger efficacy study in up to 1,700 patients.
Notably, EPOCH will enroll patients with symptomatic, mild-to-moderate Alzheimer's disease.
Is Amyloid a Useful Target at All?
John Morris told MedPage Today that the evidence from past anti-amyloid drug trials had shown convincingly that, when symptoms have developed, it's too late to reverse them by shutting down further production of beta-amyloid protein.
The time to intervene, he has come to believe, is when plaque formation is under way -- and this can now be detected in PET scans -- but before they are so extensive as to cause irreversible neuron loss.
Morris stressed that the solanezumab and MK-8931 trials could provide much useful data, but he is most excited about other studies set to get under way soon that will test anti-amyloid agents in this "preclinical" Alzheimer's disease population.
"These trials could be the best test yet of the beta-amyloid hypothesis," he said.
And what if it fails in this setting too?
"It would be extremely disappointing and also, I think, would be a major reason to reconsider" the amyloid hypothesis, Morris said.
Another researcher who has been more skeptical of the hypothesis all along is Sanjay Pimplikar, PhD, of the Cleveland Clinic in Cleveland.
In an interview with MedPage Today, he said that beta-amyloid is undoubtedly a factor in the pathology of Alzheimer's disease. But there are too many other factors that also play a role in the disease to justify singling out beta-amyloid as the point of therapeutic attack.
Morris said that the field would certainly look at tau protein -- hyperphosphorylated versions of which form toxic structures in the brain in Alzheimer's disease -- as an alternative target if the next trials of anti-amyloid drugs fail.
Pimplikar said that, in addition to tau, inflammatory processes within the brain are also clearly a factor in neurodegeneration and may be susceptible to drug therapies. The relative importance of the various contributors to Alzheimer's disease may even vary from one patient to the next.
"Let's not think of Alzheimer's as one disease, but as many diseases, like breast cancer," he toldMedPage Today. "When you have a breast cancer patient, you ask the question, is she HER2-positive? Then you treat her with Herceptin. Is she ER-positive? Then you use tamoxifen. You don't treat all the breast cancer patients the same way."
Alzheimer's disease also is not likely to respond to any given single drug in all patients -- or perhaps even in any patients.
"A monotherapy is most likely not going to work," Pimplikar said.
He added that lifestyle changes -- which recent studies have shown can be effective in reducing Alzheimer's disease risk and perhaps in reversing some symptoms -- will certainly be a component of future treatment strategies.
"Look at the cardiovascular diseases," Pimplikar said. "Of course, you can put [patients] on Lipitor. But you tell them, you must lose weight, you must control your cholesterol [intake] and your sodium."
"Similarly, for Alzheimer's disease, hopefully we'll have a drug in the next 5 years. Maybe immunotherapy will work, maybe anti-tau will work. But that particular pharmaceutical has to be supported by lifestyle changes."

Tuesday, July 17, 2012

Will the new Alzheimer's drugs work


Caregivers, and healthcare professionals, here is some great information


Here is a great dementia resource for caregivers and healthcare professinals,


Your residents will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition


Forbes


Michael Waldholz, 



In the coming months researchers will release results of several drug studies that will impact millions of Alzheimer’s victims and their families, as well as the fortunes of drugmakers,  Merck, Pfizer, Lilly and Johnson & Johnson  among others. Just as important, maybe even more so, the studies may finally provide evidence to support a controversial 20-year old theory of how the mind-robbing and lethal illness works.
But there’s plenty of reason to believe these studies tests will be inconclusive. The biggest worry is that even if the drugs work, the studies may show that to be effective, the medicines must be used much like anti-cholesterol pills, well  before the disease begins to show debilitating symptoms. If that’s true it will mean years of uncertainty about an effective treatment or cure. Alternately, the 
drugs may turn out to be complete busts, or only improve memory and thinking in a statistically negligible manner that will spark conflicting interpretations. And since there is nothing in drugmakers’ pipeline to replace the drugs being tested, negative results will force Alzheimer’s research back to square one for a disease that is already costing untold suffering and adding hundreds of millions of dollars a year in health costs that will explode as the population ages.
What follows is a review, a scorecard of sorts, of what is at stake. Much of this conversation will be front and center at an international research meeting beginning this weekend in Vancouver.
A primer: The experimental medicines all focus on attacking beta amyloid, a protein autopsies show masses in the brains of Alzheimer’s victims. According to the amyloid theory, these packets of plaque destroy brain cells over time, though exactly how they do this is still unknown. One school of scientists believes the plaques, which collect in small amounts in nearly all people as they reach old age, arise earlier and in much larger amounts in people with a predisposing genetic makeup. Another group argues that the clumping is merely the residue of some other unknown chain of events, so drugs designed to prevent or destroy amyloid will provide little if any benefit.
Alzheimer’s researchers, doctors and victims are literally holding their collective breath, hoping the studies will not only provide relief, but give scientists the kind of clear roadmap needed to fuel future investigations
A gene discovery backing the amyloid theory:  Just this week, a well-regarded research team in Icelandreported in the journal Nature that they had identified a gene that, when mutated, slows the body’s production an enzyme called beta secretase. This is a valuable discovery because beta secretase appears to play an important role in amyloid formation. Merck, Lilly and Esai are in advanced clinical studies of drugs that mimic the protective action of the gene by blocking the action of the enzyme. The Iceland group, under the direction of the gene-hunting company DeCode and its charismatic founder, Kari Stefansson, found that people with an unusual variant of the gene either don’t have the disease or don’t amass plaque in large amounts. Because the study involved a small number of people in Iceland, there is reason to be cautious about broader application.
  • The garbage collectors:  Perhaps the most important advanced study, whose results will be reported in October, involves the drug bapineuzumab, being developed by Pfizer and Johnson & Johnson and a similar drug called solanezumab from Lilly. These medicines are laboratory produced antibodies that, given through infusions, have been shown to attack and clear amyloid from the brain. Early results of another drug, Gammagard from Baxter, a combination of plaque-clearing antibodies, will also be released at the week the Alzheimer’s Association International Conference. Even a slight increase in cognition from these drugs will likely result in FDA approval and annual sales of billions of dollars. The worry is that even there though the drugs can sterilize amyloid clumps from the brain, the patient population studied may be too far advanced in their disease to be helped, or the study not be sensitive enough to detect benefits.
Still another antibody, crenezumab, being developed by Roche’s Genentech unit, is being tested in a $100 million trial in a family in Colombia where an early-onset form of the disease is common. That trial, involving about 300 relatives, won’t be completed for years.

  • The gatekeepers: Merck and Lilly are in the second of three phases of clinical trials of drugs called beta-secretase inhibitors, also referred to as BACE drugs. Unlike the antibody medicines, these drugs are being tested in pill form. The science underlying these drugs got a boost from the Iceland gene study. The idea behind these medicines is to inhibit the formation of amyloid plaque before it can cause havoc. As with the amyloid clearing drugs, there is concern that the studies underway involve patients too far into their disease.
  • The takeaway: It is clear that all the drugs in development will be most effective if used early in the disease, meaning the ability to identify those at risk is critical. Even then, the health profession and policymakers will face a dilemma. Conducting population-wide screening will be enormously expensive. Giving these medicines as long-term preventive treatments will cost many billions of dollars more. This is just one of many example of why the nation’s health bill will continue to rise sharply, with or without success in battling Alzheimer’s disease.


Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info